This is What Merck & Co. (MRK) is Doing to Mitigate Against KEYTRUDA Exclusivity Loss.
Share this article
Corporate
Score 75
Bearish
This is What Merck & Co. (MRK) is Doing to Mitigate Against KEYTRUDA Exclusivity Loss
Mar 15, 2026 21:56 UTC
MRK, XLV, IWB
Medium term
Related Articles
Score 65
Bullish
Evolus Sees Toxin Market Stabilizing, Evolysse Gaining Traction, Raises 2028 Revenue Targets at Conference
Mar 15, 23:32
Score 65
Bullish
Goodbye, Grunt Work: Oracle's AI Just Reclaimed 200,000 Hours For Doctors
Mar 15, 23:30
Score 65
Bullish
This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment
Mar 15, 23:25
Score 85
Bullish
This Fund Built a $26 Million Stake in a Medical Tech Stock That's Soaring After a $9.9 Billion Deal Announcement
Mar 15, 23:17
Stay Ahead of the Markets
Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.